Digital Nomads: Employment in the Online Gig Economy

In 1997, Tsugio Makimoto and David Manners published their future-looking manifesto Digital Nomad that, decades later, would present as a manifesto for a lifestyle movement. At the time, businesses and the US government were interested in looking at tele-commuting, productivity, and work-family balance. Critiques of a neoliberal economy provide insight into understanding the context of freelance and online, piecemeal employment. This article examines the types of employment that digital nomads engage in, based on in-depth interviews with thirty-eight self-identified digital nomads. The participants mostly originate from wealthy, industrialized nations, and have many class privileges, but are underemployed compared to what their socio-economic status would historically suggest. As most participants are in the Millennial Generation, an overview of the shifting socio-economic status of this age-cohort is examined in the United States, United Kingdom, Australia, and the European Union – notably their high educational achievements and increasingly precarious employment status. Many of the nomads were working part-time with their own micro-business, with few able to maintain full-time employment. Few have benefits such as healthcare, retirement, unemployment insurance, or family leave. While “freedom” is touted as the benefit of gig-work, by both industry management and digital nomad enthusiasts, this lifestyle marks a shift towards precarious employment – itself not a basis for economic freedom, nor security

What can southern criminology contribute to a post-race agenda?

The genesis of this paper emerged from a session of the Asian Society of Criminology Conference, Hong Kong 2015. A presentation there drew on US Bureau of Statistics data to demonstrate criminogenic differences among ‘Asians’ and other racial groups in the United States. It seemed strange that ‘Asian’ was being offered as an objective category to measure crime, when at the same conference the cultural diversity of ‘Asian’ people was highly evident. This prompted the questions: is there an Asian race, as was being suggested? And, if there is and Asian race, who belongs to this race? These questions are complex when considering that in the United Kingdom and other parts of Europe, people who originate in the Middle East and Indian subcontinent are often referred to as ‘Asian’. However, in the United States and Australia, Asians are typically deemed to be people who originate from East Asia, such as Chinese and Japanese nationals. The matter is further complicated when considering that different nationalities and cultures we lump under the broad category of Asian may consider themselves racially distinct from each other. The same might be said of ‘whites’. For example, are the French racially distinct from Germans? It was not so long ago that Irish were considered to be racially distinct from the English, although this distinction seems odd today. While the idea of race has been durable in the social sciences, it is clear that the meanings given to race are highly variable, both culturally and historically. How many races are there? Anthropology has presented as many as 100 racial categories (Walsh and Yun 2011) and, yet, certain meanings have become reified or privileged

Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study

Background Complement is likely to have a role in refractory generalised myasthenia gravis, but no approved therapies specifically target this system. Results from a phase 2 study suggested that eculizumab, a terminal complement inhibitor, produced clinically meaningful improvements in patients with anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis. We further assessed the efficacy and safety of eculizumab in this patient population in a phase 3 trial. Methods We did a phase 3, randomised, double-blind, placebo-controlled, multicentre study (REGAIN) in 76 hospitals and specialised clinics in 17 countries across North America, Latin America, Europe, and Asia. Eligible patients were aged at least 18 years, with a Myasthenia Gravis-Activities of Daily Living (MG-ADL) score of 6 or more, Myasthenia Gravis Foundation of America (MGFA) class II\ue2\u80\u93IV disease, vaccination against Neisseria meningitides, and previous treatment with at least two immunosuppressive therapies or one immunosuppressive therapy and chronic intravenous immunoglobulin or plasma exchange for 12 months without symptom control. Patients with a history of thymoma or thymic neoplasms, thymectomy within 12 months before screening, or use of intravenous immunoglobulin or plasma exchange within 4 weeks before randomisation, or rituximab within 6 months before screening, were excluded. We randomly assigned participants (1:1) to either intravenous eculizumab or intravenous matched placebo for 26 weeks. Dosing for eculizumab was 900 mg on day 1 and at weeks 1, 2, and 3; 1200 mg at week 4; and 1200 mg given every second week thereafter as maintenance dosing. Randomisation was done centrally with an interactive voice or web-response system with patients stratified to one of four groups based on MGFA disease classification. Where possible, patients were maintained on existing myasthenia gravis therapies and rescue medication was allowed at the study physician's discretion. Patients, investigators, staff, and outcome assessors were masked to treatment assignment. The primary efficacy endpoint was the change from baseline to week 26 in MG-ADL total score measured by worst-rank ANCOVA. The efficacy population set was defined as all patients randomly assigned to treatment groups who received at least one dose of study drug, had a valid baseline MG-ADL assessment, and at least one post-baseline MG-ADL assessment. The safety analyses included all randomly assigned patients who received eculizumab or placebo. This trial is registered with ClinicalTrials.gov, number NCT01997229. Findings Between April 30, 2014, and Feb 19, 2016, we randomly assigned and treated 125 patients, 62 with eculizumab and 63 with placebo. The primary analysis showed no significant difference between eculizumab and placebo (least-squares mean rank 56\uc2\ub76 [SEM 4\uc2\ub75] vs 68\uc2\ub73 [4\uc2\ub75]; rank-based treatment difference \ue2\u88\u9211\uc2\ub77, 95% CI \ue2\u88\u9224\uc2\ub73 to 0\uc2\ub796; p=0\uc2\ub70698). No deaths or cases of meningococcal infection occurred during the study. The most common adverse events in both groups were headache and upper respiratory tract infection (ten [16%] for both events in the eculizumab group and 12 [19%] for both in the placebo group). Myasthenia gravis exacerbations were reported by six (10%) patients in the eculizumab group and 15 (24%) in the placebo group. Six (10%) patients in the eculizumab group and 12 (19%) in the placebo group required rescue therapy. Interpretation The change in the MG-ADL score was not statistically significant between eculizumab and placebo, as measured by the worst-rank analysis. Eculizumab was well tolerated. The use of a worst-rank analytical approach proved to be an important limitation of this study since the secondary and sensitivity analyses results were inconsistent with the primary endpoint result; further research into the role of complement is needed. Funding Alexion Pharmaceuticals

Open data from the first and second observing runs of Advanced LIGO and Advanced Virgo

Advanced LIGO and Advanced Virgo are monitoring the sky and collecting gravitational-wave strain data with sufficient sensitivity to detect signals routinely. In this paper we describe the data recorded by these instruments during their first and second observing runs. The main data products are gravitational-wave strain time series sampled at 16384 Hz. The datasets that include this strain measurement can be freely accessed through the Gravitational Wave Open Science Center at http://gw-openscience.org, together with data-quality information essential for the analysis of LIGO and Virgo data, documentation, tutorials, and supporting software